|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: KIAA1191 |
Gene summary for KIAA1191 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | KIAA1191 | Gene ID | 57179 |
| Gene name | KIAA1191 | |
| Gene Alias | p33MONOX | |
| Cytomap | 5q35.2 | |
| Gene Type | protein-coding | GO ID | GO:0008150 | UniProtAcc | Q96A73 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 57179 | KIAA1191 | P36T-E | Human | Esophagus | ESCC | 2.71e-18 | 5.54e-01 | 0.1187 |
| 57179 | KIAA1191 | P37T-E | Human | Esophagus | ESCC | 1.18e-10 | 2.33e-01 | 0.1371 |
| 57179 | KIAA1191 | P38T-E | Human | Esophagus | ESCC | 1.13e-10 | 6.38e-01 | 0.127 |
| 57179 | KIAA1191 | P39T-E | Human | Esophagus | ESCC | 3.96e-16 | 2.41e-01 | 0.0894 |
| 57179 | KIAA1191 | P40T-E | Human | Esophagus | ESCC | 1.21e-14 | 5.08e-01 | 0.109 |
| 57179 | KIAA1191 | P42T-E | Human | Esophagus | ESCC | 1.90e-09 | 3.47e-01 | 0.1175 |
| 57179 | KIAA1191 | P44T-E | Human | Esophagus | ESCC | 2.76e-08 | 2.53e-01 | 0.1096 |
| 57179 | KIAA1191 | P47T-E | Human | Esophagus | ESCC | 9.81e-18 | 2.32e-01 | 0.1067 |
| 57179 | KIAA1191 | P48T-E | Human | Esophagus | ESCC | 3.73e-27 | 4.97e-01 | 0.0959 |
| 57179 | KIAA1191 | P49T-E | Human | Esophagus | ESCC | 8.71e-16 | 1.39e+00 | 0.1768 |
| 57179 | KIAA1191 | P52T-E | Human | Esophagus | ESCC | 4.27e-19 | 5.80e-01 | 0.1555 |
| 57179 | KIAA1191 | P54T-E | Human | Esophagus | ESCC | 1.78e-23 | 4.75e-01 | 0.0975 |
| 57179 | KIAA1191 | P56T-E | Human | Esophagus | ESCC | 1.53e-15 | 1.87e+00 | 0.1613 |
| 57179 | KIAA1191 | P57T-E | Human | Esophagus | ESCC | 7.64e-22 | 4.12e-01 | 0.0926 |
| 57179 | KIAA1191 | P61T-E | Human | Esophagus | ESCC | 8.97e-24 | 6.07e-01 | 0.099 |
| 57179 | KIAA1191 | P62T-E | Human | Esophagus | ESCC | 6.62e-66 | 1.07e+00 | 0.1302 |
| 57179 | KIAA1191 | P65T-E | Human | Esophagus | ESCC | 2.38e-23 | 2.54e-01 | 0.0978 |
| 57179 | KIAA1191 | P74T-E | Human | Esophagus | ESCC | 3.45e-37 | 1.00e+00 | 0.1479 |
| 57179 | KIAA1191 | P75T-E | Human | Esophagus | ESCC | 1.22e-34 | 6.57e-01 | 0.1125 |
| 57179 | KIAA1191 | P76T-E | Human | Esophagus | ESCC | 6.26e-25 | 3.92e-01 | 0.1207 |
| Page: 1 2 3 4 5 6 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| KIAA1191 | SNV | Missense_Mutation | rs777312602 | c.235N>C | p.Ser79Pro | p.S79P | Q96A73 | protein_coding | tolerated(0.24) | benign(0.001) | TCGA-A2-A0ET-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cytoxan | SD |
| KIAA1191 | SNV | Missense_Mutation | c.77T>C | p.Ile26Thr | p.I26T | Q96A73 | protein_coding | deleterious(0.01) | benign(0.007) | TCGA-D8-A1XK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicine+cyclophosphamide | SD | |
| KIAA1191 | SNV | Missense_Mutation | novel | c.86N>A | p.Arg29Gln | p.R29Q | Q96A73 | protein_coding | tolerated(0.12) | benign(0.314) | TCGA-E9-A5FL-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| KIAA1191 | insertion | Nonsense_Mutation | novel | c.763_764insATTAAACTTTTTTAAAGTAAAGGAGATGGTAGA | p.Leu255delinsHisTerThrPheLeuLysTerArgArgTrpTerMet | p.L255delinsH*TFLK*RRW*M | Q96A73 | protein_coding | TCGA-A8-A08H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| KIAA1191 | SNV | Missense_Mutation | novel | c.388G>A | p.Ala130Thr | p.A130T | Q96A73 | protein_coding | tolerated(0.31) | possibly_damaging(0.723) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| KIAA1191 | SNV | Missense_Mutation | novel | c.915C>G | p.Phe305Leu | p.F305L | Q96A73 | protein_coding | deleterious(0.02) | probably_damaging(0.994) | TCGA-C5-A7X5-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | carboplatin | PD |
| KIAA1191 | SNV | Missense_Mutation | rs139751460 | c.769C>T | p.Arg257Cys | p.R257C | Q96A73 | protein_coding | deleterious(0.03) | benign(0.015) | TCGA-NH-A5IV-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| KIAA1191 | SNV | Missense_Mutation | novel | c.812N>C | p.Lys271Thr | p.K271T | Q96A73 | protein_coding | deleterious(0.02) | possibly_damaging(0.747) | TCGA-F5-6814-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| KIAA1191 | insertion | Frame_Shift_Ins | novel | c.819_820insC | p.Lys274GlnfsTer18 | p.K274Qfs*18 | Q96A73 | protein_coding | TCGA-A6-2686-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| KIAA1191 | SNV | Missense_Mutation | rs202202440 | c.770N>A | p.Arg257His | p.R257H | Q96A73 | protein_coding | tolerated(0.13) | benign(0.015) | TCGA-A5-A0G1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |